| Name | Title | Contact Details |
|---|---|---|
Jennifer Prinz |
President and Chief Executive Officer | Profile |
Jennifer Muriett |
Chief Operating Officer | Profile |
New York Med And Diagnstc Center is a Kew Gardens, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Botanical Laboratories is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Ferndale, WA. To find more information about Botanical Laboratories, please visit www.botlab.com
Wimbledon Health Partners formed in 2013 to meet the need for on-site diagnostic testing at physicians’ offices. The industry leader, Wimbledon Health Partners provides physicians with state-of-the-art, in-office testing to detect circulatory conditions using vascular ultrasound and electro- and echocardiography. Nerve conduction velocity testing is also used to support diagnosis of problems related to the nervous and muscular systems. Wimbledon Athletics, the newest division of Wimbledon Health Partners, is pioneering the way for high schools, colleges and universities to test students for unsuspected heart abnormalities to help minimize sudden cardiac death among young athletes.
Whitecourts Interagency Food Bank is a Whitecourt, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.